Key result
Secondary hyperaldosteronism in HFpEF is linked to ~242% higher odds of LV diastolic dysfunction and hypertrophy.
Why the study?
The study was conducted to evaluate the relationship between plasma aldosterone levels and left ventricular structure and function in patients with heart failure with preserved ejection fraction.
Is hyperaldosteronism associated with worse left ventricular structure and function in patients with HFpEF?
Observational (n=158)
Is hyperaldosteronism associated with worse left ventricular structure and function in patients with HFpEF?
Effect estimate: OR 3.42 (95% CI 1.65-9.64)
p-value: p=0.001
In patients with HFpEF, secondary hyperaldosteronism is independently associated with worse LV diastolic dysfunction and concentric hypertrophy.
No takes yet. Share an insight, caveat, or question.
May signal higher-risk HFpEF phenotype; leaves open whether aldosterone antagonism improves outcomes.
A. N. Shevelok (2021) conducted an observational in Heart failure with preserved ejection fraction (HFpEF) (n=158). Hyperaldosteronism vs. Normal aldosterone levels was evaluated on E/e' (marker of LV diastolic dysfunction) (OR 3.42, 95% CI 1.65-9.64, p=0.001). Secondary hyperaldosteronism in patients with HFpEF is independently associated with LV diastolic dysfunction (OR 3.42; 95% CI 1.65-9.64; p=0.001) and concentric hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: